Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with placebo at week 12. The safety profile of ICP-488 was similar to placebo. ORLANDO — A once ...

Last month, the company completed enrolment for its Phase IIb trial of VYN201 gel, also known as repibresib ... "Vyne doses first participant in Phase Ib plaque psoriasis treatment trial" was ...

These include plaque psoriasis, guttate psoriasis ... Apply a thin layer of aloe vera gel onto your skin to reduce itching, ...

ESK-001, a tyrosine kinase 2 inhibitor, may be a promising new oral treatment for plaque psoriasis. Patients taking ESK-001 twice daily maintained skin clearance up to a year. ORLANDO — Patients ...

(RTTNews) - Johnson & Johnson (JNJ) announced new icotrokinra (JNJ-2113) data from its Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO ...